Skip to main content

Advertisement

SpringerLink
Log in

Multidisciplinary Management of Rectal Cancer with Synchronous Resectable Liver Metastases

  • Hot Topic
  • Published:
Current Colorectal Cancer Reports

Abstract

Liver metastases are the most common manifestation of metastatic disease in colorectal cancer, and synchronous metastases occur in around 50% of patients. In rectal cancer, this presentation is uniquely challenging because of issues related to competing treatments and sequencing of therapy. Though there is published data on the management of rectal tumor and liver metastasis from colorectal cancer (CRC) individually, data on the management of synchronous disease is sparse. This is a heterogeneous group of patients and should be managed on a case by case basis and with multidisciplinary evaluation. To this end, we present four cases that highlight several of the issues associated with the management presenting with resectable synchronous liver metastasis from rectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  2. Siegel R, Ward E, Brawley O, et al. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Ca-a Cancer J Clin. 2011;61:212–36.

    Article  Google Scholar 

  3. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Instit:djs491, 2013.

  4. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438–50.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Reddy SK, Zorzi D, Lum YW, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16:1809–19.

    Article  PubMed  Google Scholar 

  6. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052–64.

    Article  PubMed  PubMed Central  Google Scholar 

  7. • Viganò L, Capussotti L, De Rosa G, et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258:731–42. Retrospective study describing tumor features such as TRG as well as liver damage that may have an effect on survival.

  8. Shindoh J, Loyer EM, Kopetz S. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol:JCO. 2012;45:2854.

    Google Scholar 

  9. AlGizawy SM, Essa HH, Ahmed BM. Chemotherapy alone for patients with stage II/III rectal cancer undergoing radical surgery. Oncologist. 2015;20:752–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. •• Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8. Pilot study showing that selected patients with rectal cancer may not need radiation.

  11. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109–17.

    Article  PubMed  Google Scholar 

  12. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96.

    Article  PubMed  Google Scholar 

  13. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.

    Article  CAS  PubMed  Google Scholar 

  14. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845–53.

    Article  PubMed  Google Scholar 

  15. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420–5.

    Article  PubMed  Google Scholar 

  16. Ychou M, Rivoire M, Thezenas S, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. the METHEP trial. Ann Surg Oncol. 2013;20:4289–97.

    Article  PubMed  Google Scholar 

  17. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.

    Article  CAS  PubMed  Google Scholar 

  18. Vauthey J-N, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.

    Article  CAS  PubMed  Google Scholar 

  19. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7:1034–44.

    Article  PubMed  Google Scholar 

  20. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.

    Article  PubMed  Google Scholar 

  21. Walter H, Thomas A. Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review. Br J Cancer. 2013;108:2417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Aussilhou B, Dokmak S, Faivre S, et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol. 2009;16:1553–9.

    Article  PubMed  Google Scholar 

  23. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.

    Article  CAS  PubMed  Google Scholar 

  24. • Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. Lancet Oncol. 2014;15:601–11. Randomized controlled trial evaluating the role of cetuximab in resectable liver disease in CRC patients.

    Article  CAS  PubMed  Google Scholar 

  25. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol. 2005;23:8490–9.

    Article  PubMed  Google Scholar 

  26. Malik H, Hamady Z, Adair R, et al. Prognostic influence of multiple hepatic metastases from colorectal cancer. Europ J Surg Oncol (EJSO). 2007;33:468–73.

    Article  CAS  Google Scholar 

  27. Pulitanò C, Bodingbauer M, Aldrighetti L, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011;18:1380–8.

    Article  PubMed  Google Scholar 

  28. Brouquet A, Mortenson MM, Vauthey J-N, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934–41.

    Article  PubMed  Google Scholar 

  29. Martin RC, Augenstein V, Reuter NP, et al. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg. 2009;208:842–50.

    Article  PubMed  Google Scholar 

  30. Nordlinger B, Sorbye H, Glimelius B, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. Lancet Oncol. 2013;14:1208–15.

    Article  CAS  PubMed  Google Scholar 

  31. Ychou M, Hohenberger W, Thezenas S, et al A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol:mdp236, 2009.

  32. Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31:4465–70.

    Article  PubMed  Google Scholar 

  33. Bujko K, Nowacki M, Nasierowska‐Guttmejer A, et al. Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.

    Article  CAS  PubMed  Google Scholar 

  34. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30:3827–33.

    Article  PubMed  Google Scholar 

  35. Kim JW, Kim YB, Kim N-K, et al. The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. Radiat Oncol. 2010;5:1.

    Article  Google Scholar 

  36. Butte JM, Gonen M, Ding P, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer. 2012;118:5414–23.

    Article  PubMed  Google Scholar 

  37. Van Hooft JE, Van Halsema EE, Vanbiervliet G, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2014;46:990–1053.

    Article  PubMed  Google Scholar 

  38. Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.

    Article  PubMed  Google Scholar 

  39. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.

    Article  CAS  PubMed  Google Scholar 

  40. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125–34.

    Article  PubMed  Google Scholar 

  41. Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep. 2009;11:200–8.

    Article  PubMed  Google Scholar 

  42. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–58.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Anaya DA, Blazer DG, Abdalla EK. Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma, Seminars in interventional radiology, © Thieme Medical Publishers. 2008: 110–122.

  44. Orcutt ST, Kobayashi K, Sultenfuss M et al. Portal vein embolization as an oncosurgical strategy prior to major hepatic resection: anatomic, surgical, and technical considerations. Frontiers Surg. 2016:3.

  45. • Beal I, Anthony S, Papadopoulou A et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. British J Radiol. 2014. Series describing liver hypertrophy with and without post-PVE chemotherapy.

  46. • Fischer C, Melstrom LG, Arnaoutakis D, et al. Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg. 2013;148:1103–8. Retrospective data describing liver hypertrophy after PVE with chemotherapy.

Download references

Acknowledgements

This article was reviewed by Dr. Richard D. Kim of the H. Lee Moffitt Cancer Center & Research Institute.

Author information

Authors and Affiliations

  1. Section of Hepatobiliary Tumors, Department of Gastrointestinal Oncology, Moffitt Cancer Center, FOB 2nd floor, 12902 Magnolia Drive, Tampa, FL, 33612, USA

    Nishi Kothari & Daniel A. Anaya

Authors
  1. Nishi Kothari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. Anaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Nishi Kothari or Daniel A. Anaya.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kothari, N., Anaya, D.A. Multidisciplinary Management of Rectal Cancer with Synchronous Resectable Liver Metastases. Curr Colorectal Cancer Rep 13, 1–9 (2017). https://doi.org/10.1007/s11888-017-0346-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-017-0346-9

Keywords

Search

Navigation